Jenburkt Pharma: Dilip Bhuta Re-appointed as Whole Time Director & CFO

Jenburkt Pharmaceuticals Ltd's board re-appointed Shri Dilip H. Bhuta as the Whole Time Director and CFO for five years, effective April 1, 2027, until March 31, 2032, subject to member approval at the 41st Annual General Meeting. The board also approved a dividend of ₹20.70 per equity share for FY26. The 41st AGM is scheduled for September 4, 2026, via video conferencing. Standalone audited financial results for the quarter and year ended March 31, 2026, were approved, showing a revenue from operations of ₹16,874.06 Lacs for the year.